GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice [PDF]
, 2022 Dual agonists activating the peroxisome proliferator-activated receptors alpha and gamma (PPARɑ/ɣ) have beneficial effects on glucose and lipid metabolism in patients with type 2 diabetes, but their development was discontinued due to potential adverse ...
Bakhti, Mostafa +39 more
core +4 more sources
Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study [PDF]
, 2018 In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits.
Avogaro A +8 more
core +2 more sources
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu +4 more
core +5 more sources
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]
, 2016 Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo +4 more
core +3 more sources
Cardiovascular Diabetology, 2020 Background Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice.
Chun-Ting Yang +3 more
doaj +1 more source
When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]
, 2016 Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier +4 more
core +2 more sources
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss:Findings from the Shanghai Osteoarthritis Cohort [PDF]
, 2023 Objective: Obesity is a risk factor for knee osteoarthritis (KOA) development and progression. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are indicated for type 2 diabetes mellitus (T2DM) and obesity.
Cai, Qianying +8 more
core +2 more sources
Cardiovascular Diabetology, 2022 Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2
Dario Giugliano +6 more
doaj +1 more source
A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation. [PDF]
JMIR Form ResRichards R +3 more
europepmc +2 more sources
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks. DUAL VIII, a randomized trial designed to resemble clinical practice [PDF]
, 2020 This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N =
Aroda, V. R. +7 more
core +1 more source